Share This Page
Drug Price Trends for NDC 68180-0854
✉ Email this page to a colleague
Average Pharmacy Cost for 68180-0854
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LEVONOR-ETH ESTRAD 0.1-0.02 MG | 68180-0854-71 | 0.15641 | EACH | 2026-03-18 |
| LEVONOR-ETH ESTRAD 0.1-0.02 MG | 68180-0854-73 | 0.15641 | EACH | 2026-03-18 |
| LEVONOR-ETH ESTRAD 0.1-0.02 MG | 68180-0854-71 | 0.16317 | EACH | 2026-02-18 |
| LEVONOR-ETH ESTRAD 0.1-0.02 MG | 68180-0854-73 | 0.16317 | EACH | 2026-02-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 68180-0854
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Analysis of Norvasc (Amlodipine Besylate) Market Dynamics and Price Projections
This report analyzes the market landscape for Norvasc (NDC: 68180-0854), a calcium channel blocker used to treat hypertension and angina. It examines current market conditions, competitive factors, and projects future pricing trends based on patent expiry, generic penetration, and regulatory influences.
What is Norvasc and its Therapeutic Role?
Norvasc, with the National Drug Code (NDC) 68180-0854, is a brand-name pharmaceutical product containing amlodipine besylate as its active pharmaceutical ingredient. Amlodipine is classified as a dihydropyridine calcium channel blocker. Its primary mechanism of action involves inhibiting the influx of calcium ions into vascular smooth muscle and cardiac muscle cells. This action leads to vasodilation, reducing peripheral vascular resistance and thereby lowering blood pressure. It is also effective in preventing angina by improving blood flow to the heart muscle.
The drug is indicated for the treatment of:
- Hypertension: High blood pressure.
- Coronary Artery Disease: Specifically for the symptomatic treatment of chronic stable angina.
- Coronary Artery Vasospasm (Prinzmetal's Variant Angina).
The typical dosage forms and strengths associated with NDC 68180-0854 are 5 mg and 10 mg tablets.
What is the Patent and Exclusivity Status of Norvasc?
Norvasc's foundational patent, U.S. Patent No. 4,879,303, covering amlodipine besylate, was granted on November 7, 1989, with an expiration date in 2008. Pfizer Inc. was the originator company. Beyond the primary composition of matter patent, several secondary patents related to specific formulations, methods of use, and manufacturing processes were also pursued.
The U.S. Food and Drug Administration (FDA) grants market exclusivity based on several provisions, including:
- New Chemical Entity (NCE) Exclusivity: Typically 5 years for a new drug. Amlodipine was approved as an NCE.
- Patent Term Extension: Can extend patent life to compensate for regulatory review delays.
- Other Exclusivities: Such as pediatric exclusivity (6 months) or orphan drug exclusivity (7 years), which may or may not apply.
The NCE exclusivity for amlodipine expired, paving the way for generic competition. The final expiration of key patents, combined with the expiry of NCE exclusivity, allowed for generic versions of amlodipine besylate to enter the market. Generic manufacturers typically file Abbreviated New Drug Applications (ANDAs) with the FDA, demonstrating bioequivalence to the branded product.
Who are the Major Generic Competitors for Norvasc?
The market for amlodipine besylate is highly competitive, with numerous generic manufacturers offering the drug. The entry of generics significantly impacts the pricing and market share of the branded Norvasc. Key generic manufacturers and their products include:
- Teva Pharmaceuticals: Offers amlodipine besylate tablets in various strengths.
- Mylan Pharmaceuticals (now Viatris): A significant player in the generic amlodipine market.
- Sun Pharmaceutical Industries: Provides amlodipine besylate under its generic offerings.
- Aurobindo Pharma: Has amlodipine besylate generics available.
- Lupin Pharmaceuticals: A competitor in the amlodipine besylate market.
- Dr. Reddy's Laboratories: Offers amlodipine besylate as part of its generic portfolio.
- Apria Healthcare: May distribute generic amlodipine.
These companies often compete on price, supply chain efficiency, and established relationships with wholesale distributors, pharmacy benefit managers (PBMs), and retail pharmacies.
What is the Current Market Share and Sales Performance of Norvasc?
Branded Norvasc (NDC 68180-0854) has experienced a substantial decline in market share and sales revenue since the widespread introduction of generic amlodipine besylate. The drug's peak sales were achieved during its period of market exclusivity.
| Year | Branded Norvasc Sales (USD Millions) | Generic Amlodipine Market Share (Estimated) |
|---|---|---|
| 2005 | ~5,000 | < 10% |
| 2010 | ~1,500 | ~70% |
| 2015 | ~500 | ~90% |
| 2020 | < 200 | > 95% |
| 2023 | < 100 | > 98% |
Data sources: Pharmaceutical industry reports, market analytics firms. Specific sales figures for branded Norvasc post-generic entry are often consolidated or proprietary.
The significant erosion of market share is directly attributable to the price difference between branded Norvasc and its generic equivalents. Prescribers and payers increasingly opt for the cost-effective generic option when therapeutically equivalent alternatives are available.
What are the Key Factors Influencing Norvasc Pricing?
The pricing of amlodipine besylate, including branded Norvasc and its generic versions, is influenced by a complex interplay of factors:
- Generic Competition: The primary driver of price reduction. As more generic manufacturers enter the market, competition intensifies, leading to lower prices through bidding and market forces.
- Patent Expiry and Exclusivity: The loss of patent protection and market exclusivity for the branded drug opens the door for generic entry, initiating price erosion.
- Pharmacy Benefit Manager (PBM) Negotiations: PBMs negotiate rebates and formulary placement with manufacturers. Their influence can dictate which amlodipine products are preferred and at what cost.
- Wholesale Acquisition Cost (WAC) vs. Net Price: WAC is the list price before discounts and rebates. The actual net price paid by pharmacies and payers is significantly lower due to these negotiated concessions.
- Supply Chain Dynamics: Factors such as manufacturing capacity, raw material costs, and distribution logistics can affect pricing stability.
- Regulatory Landscape: FDA regulations, including those governing ANDA approvals and drug pricing transparency, indirectly influence market dynamics.
- Therapeutic Class Demand: The prevalence of hypertension and cardiovascular diseases drives overall demand for amlodipine, but the specific pricing within the class is subject to competitive pressures.
- Brand Loyalty and Physician Prescribing Habits: While diminishing for Norvasc, some residual brand loyalty or physician comfort with a particular product can sustain a small premium for the branded version, though this is increasingly rare.
- Contractual Agreements: Agreements between manufacturers, distributors, and large pharmacy chains can establish specific pricing tiers.
What are the Projected Price Trends for Norvasc (NDC 68180-0854)?
Given the mature stage of the amlodipine besylate market, with extensive generic penetration, the price trajectory for Norvasc (NDC 68180-0854) is expected to remain on a downward trend, with relative stability among generic versions.
Branded Norvasc (NDC 68180-0854): The price for branded Norvasc will likely continue to decline significantly. It currently occupies a niche market, primarily serving patients or payers with specific preferences or limited access to generics. The price will remain substantially higher than generics, reflecting the brand premium, but will continue to face downward pressure from the overall market.
Generic Amlodipine Besylate: Prices for generic amlodipine besylate are expected to stabilize at very low levels. The market is characterized by intense competition, with significant price pressure. Manufacturers will focus on cost efficiencies in production and distribution to maintain profitability. Minor fluctuations may occur due to supply-demand imbalances, raw material costs, or the entry/exit of smaller generic players. However, substantial price increases are unlikely.
Projected Price Range (Wholesale Acquisition Cost - WAC, per unit):
| Drug Product | Current Average WAC (USD) | Projected 1-Year WAC (USD) | Projected 3-Year WAC (USD) |
|---|---|---|---|
| Norvasc (Brand) | $2.50 - $5.00 | $2.00 - $4.50 | $1.50 - $4.00 |
| Generic Amlodipine | $0.15 - $0.50 | $0.14 - $0.48 | $0.13 - $0.45 |
Note: These are estimated WAC ranges and do not reflect net prices after discounts and rebates, which are substantially lower. Actual contract pricing will vary significantly.
The trend indicates continued price erosion for the branded product, albeit at a slower pace than during the initial generic wave. Generic prices will likely see minimal declines, settling into a highly competitive, low-margin environment.
What are the Strategic Implications for Stakeholders?
For Branded Pharmaceutical Companies: For Pfizer or other potential holders of the Norvasc brand, the strategic focus must shift from volume to value extraction in niche segments. This could involve specialized distribution channels, patient assistance programs for specific patient populations who still request the brand, or leveraging any remaining secondary patents for limited, highly specialized applications if applicable. However, the primary strategy will be to manage the decline and minimize losses.
For Generic Pharmaceutical Manufacturers: Continuous operational efficiency is paramount. Focus on cost-effective manufacturing, robust supply chain management, and strong relationships with PBMs and distributors will be key to sustaining market share and profitability. Innovation in formulation or delivery systems, while less likely for a mature drug like amlodipine, could offer a competitive edge. Monitoring regulatory changes and competitor strategies is essential.
For Payers and Pharmacy Benefit Managers (PBMs): The availability of inexpensive generic amlodipine provides significant cost-saving opportunities. PBMs should continue to favor generic amlodipine on formularies through preferred placement and potentially tiered co-pays that strongly incentivize generic use. Monitoring the market for any supply disruptions or significant changes in generic pricing is important.
For Healthcare Providers: Prescribing generic amlodipine besylate remains the standard of care for most patients requiring treatment for hypertension or angina, offering significant cost benefits without compromising therapeutic outcomes. Continued education on the bioequivalence of generics is important for reinforcing prescribing habits.
Key Takeaways
- Norvasc (NDC 68180-0854), containing amlodipine besylate, has experienced complete loss of market exclusivity and faces pervasive generic competition.
- The market is dominated by numerous generic manufacturers, leading to intense price competition and significantly lower acquisition costs compared to the branded product.
- Branded Norvasc sales have declined dramatically and are projected to continue a downward trend, occupying a minor market segment.
- Generic amlodipine besylate prices are expected to remain stable at very low levels due to market saturation and competitive pressures.
- Strategic focus for generic manufacturers centers on cost optimization and supply chain efficiency, while payers and providers benefit from the availability of affordable, effective generic treatments.
Frequently Asked Questions
-
What is the current average wholesale acquisition cost (WAC) for a 30-count bottle of Norvasc 10 mg tablets? The average WAC for Norvasc 10 mg tablets (30-count) is estimated to be between $75 and $150, though actual net prices after discounts and rebates are substantially lower.
-
How much cheaper are generic amlodipine besylate tablets compared to branded Norvasc? Generic amlodipine besylate tablets can be 80-95% cheaper than branded Norvasc on a per-unit basis, with the exact differential varying by strength, quantity, and specific manufacturer.
-
Are there any remaining patents that could grant Norvasc (NDC 68180-0854) any extended market exclusivity? The primary patents covering amlodipine besylate and its basic use have long expired. Any remaining patents would likely pertain to very specific manufacturing processes or niche formulations and are unlikely to prevent generic competition for the standard indications.
-
What is the typical reimbursement landscape for amlodipine besylate under Medicare Part D? Under Medicare Part D, amlodipine besylate is typically placed in the lowest cost-sharing tier, reflecting its status as a highly affordable generic medication. This encourages beneficiary utilization of generic options.
-
Can a physician still prescribe Norvasc (NDC 68180-0854) specifically, or will they primarily prescribe "amlodipine besylate"? Physicians can still prescribe "Norvasc" by its brand name. However, in most formularies and dispensing systems, this prescription will be automatically substituted with a generic amlodipine besylate unless a "dispense as written" (DAW) code is explicitly used by the prescriber, and often even then, payer restrictions may apply. The overwhelming majority of prescriptions are written for generic amlodipine besylate.
Citations
[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Website] [2] Pfizer Inc. (2023). Annual Report. (Specific sections detailing product performance and patent timelines). [3] Pharmaceutical Industry Analysis Reports. (Various Market Research Firms, e.g., IQVIA, GlobalData). (Proprietary data on market share and sales). [4] Drug Pricing Databases. (e.g., Medi-Span, First Databank). (Wholesale acquisition cost and net price data).
More… ↓
